Global Health Crises and Strategic Approaches

The contemporary global public health and biosecurity architecture is under profound strain from two major macro-level biological threat matrices: the phenomenon of Antimicrobial Resistance (AMR), which exhibits an exponential surge in incidence, and hypothetical "Disease X" scenarios carrying the potential to transcend the epidemiological boundaries of high-mortality pathogens such as Ebola, Hantavirus, or SARS-CoV-2.

The World Health Organization (WHO), FDA, and EMA classify this complex clinical landscape as "one of the top 10 global public health threats facing humanity," designating it under the highest priority tier as an "advanced unmet urgent medical need." Engineering an effective and sustainable response to these crises necessitates the discovery of innovative molecular/therapeutic platforms that transcend conventional methodologies, compelling a radical paradigm shift in medical science.

Our Solution Strategy: A New "Pathogen-Agnostic, Host-Directed" Paradigm

At the core of these global crises reside pathogens characterized by heterogeneous pathophysiological profiles and capable of evading host defense mechanisms. The evolutionary adaptation and dissemination potential of these high-mortality pathogens present an enduring threat to public health. Both the escalation of AMR and the emergence of unpredictable pandemic variants mandate that conventional therapeutic paradigms be augmented with innovative scientific strategies.

In these domains, where existing pharmacological modalities struggle to deliver adequate responses in isolation, exploring methodologies that modulate the organism's immune responses and fortify biological resilience at the epigenetic and systemic levels—in addition to purely pathogen-centric solutions—emerges as a vital scientific imperative.

The Host-Directed strategy developed by AVB Biotechnology bypasses direct pathogen targeting, fundamentally relying instead on the modulation of the host's innate defense mechanisms via epigenetic regulations. Within the scope of this research concept, our primary objectives include:

• Regulating and enhancing the biocidal potential of key effector cells—such as neutrophils, macrophages, and microglia—with a rigorous focus on pathogen clearance.

• Developing a "pathogen-agnostic" cellular response capable of operating independently of the specific pathogen strain.

Sustainable Therapeutic Potential

Preclinical studies and preliminary evaluations of clinical trials conducted by our team demonstrate that this pathogen-agnostic mechanism effectively optimizes targeted biological and cellular responses. These cumulative data indicate that our methodological approach offers a sustainable therapeutic potential in infection management and resistant pathogen crises, operating independently of conventional mechanisms.

The information contained in this section reflects the vision and ongoing R&D initiatives of AVB Biotechnology; it does not constitute an approved medical diagnosis or therapeutic recommendation.